Literature DB >> 6172626

Enhanced expression of melanoma-associated antigens and beta 2-microglobulin on cultured human melanoma cells by interferon.

S K Liao, P C Kwong, M Khosravi, P B Dent.   

Abstract

The effect of human leukocyte interferon (IFN) on the in vitro growth and expression of melanoma-associated antigens (MAA). beta 2-microglobulin (beta 2m) and HLA-DR antigen on cultured human melanoma cells was studied. Exposure of melanoma cells to IFN for 64 hours resulted in a dose-dependent inhibition of growth with 46% reduction in cell number at 10(3) U IFN/ml and 74% reduction at 10(5) U/ml. Quantitative absorption experiments in the mixed hemadsorption assay determined that the expression of MAA and beta 2m on treated cells was enhanced at 10(2)-10(5) U IFN/ml, twofold to fivefold for MAA and fivefold to twelvefold for beta 2m. No change was seen in HLA-DR antigen expression. The IFN-induced enhancement of MAA and beta 2m could be detected as early as after 16 hours and a maximum expression was reached at 96 hours after IFN exposure. The IFN-induced enhancement of MAA and beta 2m on melanoma cells was reversible. Studies with melanoma cells grown in stationary phase and serum-deprived conditions indicated that IFN-induced augmentation of MAA and beta 2m did not require cell proliferation. The data suggest that the effect of IFN on antigen expression is independent of its effect on cell growth. Further studies are needed to fully elucidate the mechanism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6172626

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

Review 1.  IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.

Authors:  M Hokland; P Basse; J Justesen; P Hokland
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

2.  Heterogeneous expression of a murine B16 melanoma-associated antigen correlates with cell cycle.

Authors:  S P Leong; P D Noguchi; R E Cunningham; T Takami; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 3.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Lysis of small cell carcinoma of the lung tumor cell lines by gamma interferon-activated allogeneic peripheral blood mononuclear cells: abrogation of killing by pretreatment of tumor cells with gamma interferon.

Authors:  E D Ball; K E Nichols; O S Pettengill; G D Sorenson; M W Fanger
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

6.  Positive interactions between human interferon and cepharanthin against human cancer cells in vitro and in vivo.

Authors:  M Ono; N Tanaka; K Orita
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.

Authors:  C Natoli; C Garufi; N Tinari; M D'Egidio; G Lesti; L A Gaspari; R Visini; S Iacobelli
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.